Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.
Publication
, Conference
Pivot, X; Pegram, MD; Cortes, J; Luftner, D; Rugo, HS; Lyman, GH; Curigliano, G; Bondarenko, I; Dvorkin, M; Yoon, YC; Kim, Y; Kim, C
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Rugo, H. S., Lyman, G. H., … Kim, C. (2020). Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Pivot, Xavier, Mark D. Pegram, Javier Cortes, Diana Luftner, Hope S. Rugo, Gary H. Lyman, Giuseppe Curigliano, et al. “Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Pivot X, Pegram MD, Cortes J, Luftner D, Rugo HS, Lyman GH, et al. Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Pivot, Xavier, et al. “Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.
Pivot X, Pegram MD, Cortes J, Luftner D, Rugo HS, Lyman GH, Curigliano G, Bondarenko I, Dvorkin M, Yoon YC, Kim Y, Kim C. Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. JOURNAL OF CLINICAL ONCOLOGY. 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences